Comments on: Multiple Sclerosis Treatments Presented at AAN Annual Meeting This Week http://blog.bioasis.ca/?p=890 The Science of Melanotransferrin (p97) Thu, 02 Sep 2010 15:27:11 +0000 hourly 1 http://wordpress.org/?v=3.0 By: Mahesh http://blog.bioasis.ca/?p=890&cpage=1#comment-49 Mahesh Tue, 02 Jun 2009 21:03:05 +0000 http://blog.bioasis.ca/?p=890#comment-49 Thanks for your comment Cate. I apologize for the mistake. NT-201 is indeed for the treatment of cervical dystonia and blepharospasm. My intent was to make note of all treatments presented at AAN that related to movement disorders. The post has been updated. Thanks for your comment Cate. I apologize for the mistake. NT-201 is indeed for the treatment of cervical dystonia and blepharospasm. My intent was to make note of all treatments presented at AAN that related to movement disorders. The post has been updated.

]]> By: Cate http://blog.bioasis.ca/?p=890&cpage=1#comment-45 Cate Mon, 01 Jun 2009 21:19:10 +0000 http://blog.bioasis.ca/?p=890#comment-45 The information provided in the following statement is incorrect. Merz Pharmaceuticals is presenting new positive data on three clinical trials with its dementia drug Xeomin (NT-201). NT-201 is a form of botulinum toxin type A without complexing proteins and is being studied for the treatment of cervical dystonia and blepharospasm, not AD. The information provided in the following statement is incorrect. Merz Pharmaceuticals is presenting new positive data on three clinical trials with its dementia drug Xeomin (NT-201).

NT-201 is a form of botulinum toxin type A without complexing proteins and is being studied for the treatment of cervical dystonia and blepharospasm, not AD.

]]>